Real World Biologic Use and Switch Patterns in Severe Asthma: Data from the International Severe Asthma Registry and the US CHRONICLE Study

Effect of Anti-IL5, Anti-IL5R, Anti-IL13 Therapy on Asthma Exacerbations: A Network Meta-analysis

(2020) Richard P. Ramonell et al.   LUNG

Therapeutic Potential of Dupilumab in the Treatment of Chronic Rhinosinusitis with Nasal Polyps: Evidence to Date

(2020) Jean Kim et al.   Therapeutics and Clinical Risk Management

Antibodies targeting the interleukin-5 signaling pathway used as add-on therapy for patients with severe eosinophilic asthma: a review of the mechanism of action, efficacy, and safety of the subcutaneously administered agents, mepolizumab and benralizumab

(2020) Georgios Hillas et al.   Expert Review of Respiratory Medicine

Biologic and maintenance systemic corticosteroid therapy among US subspecialist-treated patients with severe asthma

(2020) Wendy C. Moore et al.   ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY

Clinical use of biologics for asthma treatment by allergy specialists

(2020) Merin Kuruvilla et al.   ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY

International severe asthma registry (ISAR): protocol for a global registry

(2020) J. Mark FitzGerald et al.   BMC Medical Research Methodology

Significant improvement in lung function and asthma control after benralizumab treatment for severe refractory eosinophilic asthma

(2020) Francesco Menzella et al.   PULMONARY PHARMACOLOGY & THERAPEUTICS

Characterization of severe asthma worldwide: data from the International Severe Asthma Registry (ISAR)

(2019) Wang Eileen et al.   CHEST

Dual blockade of IL‐4 and IL‐13 with dupilumab, an IL‐4Rα antibody, is required to broadly inhibit type 2 inflammation

(2019) Audrey Le Floc’h et al.   ALLERGY

International Severe Asthma Registry

(2019) G. Walter Canonica et al.   CHEST

An expert consensus framework for asthma remission as a treatment goal

(2019) Andrew Menzies-Gow et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma

(2018) Mario Castro et al.   NEW ENGLAND JOURNAL OF MEDICINE

Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies

(2018) J Mark FitzGerald et al.   Lancet Respiratory Medicine

Consequences of long-term OCS therapy and its side effects in severe asthma in adults – A focused review of the impact data in the literature

(2018) Timm Volmer et al.   EUROPEAN RESPIRATORY JOURNAL

Development of the International Severe Asthma Registry (ISAR): a modified Delphi study

(2018) Lakmini Bulathsinhala et al.   Journal of Allergy and Clinical Immunology-In Practice

Role of Biologics in Asthma

(2018) Mary Clare McGregor et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL study

(2017) Frank C. Albers et al.   JOURNAL OF ASTHMA

Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials

(2015) Mario Castro et al.   Lancet Respiratory Medicine

Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma

(2014) Hector G. Ortega et al.   NEW ENGLAND JOURNAL OF MEDICINE